JPWO2021045159A1 - - Google Patents
Info
- Publication number
- JPWO2021045159A1 JPWO2021045159A1 JP2021544029A JP2021544029A JPWO2021045159A1 JP WO2021045159 A1 JPWO2021045159 A1 JP WO2021045159A1 JP 2021544029 A JP2021544029 A JP 2021544029A JP 2021544029 A JP2021544029 A JP 2021544029A JP WO2021045159 A1 JPWO2021045159 A1 JP WO2021045159A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050332A JP2025094217A (ja) | 2019-09-04 | 2025-03-25 | 併用医薬による糖尿病の治療又は予防方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019161526 | 2019-09-04 | ||
| JP2019161526 | 2019-09-04 | ||
| PCT/JP2020/033463 WO2021045159A1 (ja) | 2019-09-04 | 2020-09-03 | 併用医薬による糖尿病の治療又は予防方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050332A Division JP2025094217A (ja) | 2019-09-04 | 2025-03-25 | 併用医薬による糖尿病の治療又は予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021045159A1 true JPWO2021045159A1 (https=) | 2021-03-11 |
| JPWO2021045159A5 JPWO2021045159A5 (https=) | 2023-09-11 |
| JP7692832B2 JP7692832B2 (ja) | 2025-06-16 |
Family
ID=74852211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544029A Active JP7692832B2 (ja) | 2019-09-04 | 2020-09-03 | 併用医薬による糖尿病の治療又は予防方法 |
| JP2025050332A Withdrawn JP2025094217A (ja) | 2019-09-04 | 2025-03-25 | 併用医薬による糖尿病の治療又は予防方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050332A Withdrawn JP2025094217A (ja) | 2019-09-04 | 2025-03-25 | 併用医薬による糖尿病の治療又は予防方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230119894A1 (https=) |
| EP (2) | EP4026564A4 (https=) |
| JP (2) | JP7692832B2 (https=) |
| KR (1) | KR20220056219A (https=) |
| CN (2) | CN119113123A (https=) |
| AU (1) | AU2020341926B2 (https=) |
| BR (1) | BR112022003323A2 (https=) |
| CA (1) | CA3151909A1 (https=) |
| MX (1) | MX2022002683A (https=) |
| WO (1) | WO2021045159A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7760370B2 (ja) * | 2019-09-04 | 2025-10-27 | 日本たばこ産業株式会社 | 慢性腎臓病の治療又は予防方法 |
| CA3175131A1 (en) * | 2020-03-19 | 2021-09-23 | Chihiro Okuma | Treatment or prevention method for chronic heart failure |
| AU2022340358A1 (en) * | 2021-09-02 | 2024-01-04 | Daewoong Therapeutics Inc. | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor |
| WO2025245592A1 (en) * | 2024-05-31 | 2025-12-04 | Aché Laboratórios Farmacêuticos S.A. | Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011002011A1 (ja) * | 2009-07-01 | 2011-01-06 | キッセイ薬品工業株式会社 | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |
| JP2015516419A (ja) * | 2012-05-10 | 2015-06-11 | イーライ リリー アンド カンパニー | Ｓｇｌｔ１阻害剤としてのピラゾール化合物 |
| JP2018115216A (ja) * | 2011-08-31 | 2018-07-26 | 日本たばこ産業株式会社 | ピラゾール化合物及びその医薬用途 |
| JP7130588B2 (ja) * | 2018-04-04 | 2022-09-05 | 日本たばこ産業株式会社 | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 |
| JP7206132B2 (ja) * | 2018-03-01 | 2023-01-17 | 日本たばこ産業株式会社 | メチルラクタム環化合物及びその医薬用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| CN110066302B (zh) * | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
| JP7760370B2 (ja) * | 2019-09-04 | 2025-10-27 | 日本たばこ産業株式会社 | 慢性腎臓病の治療又は予防方法 |
| CA3175131A1 (en) * | 2020-03-19 | 2021-09-23 | Chihiro Okuma | Treatment or prevention method for chronic heart failure |
-
2020
- 2020-09-03 US US17/639,552 patent/US20230119894A1/en active Pending
- 2020-09-03 CN CN202411355046.5A patent/CN119113123A/zh active Pending
- 2020-09-03 WO PCT/JP2020/033463 patent/WO2021045159A1/ja not_active Ceased
- 2020-09-03 BR BR112022003323A patent/BR112022003323A2/pt unknown
- 2020-09-03 CA CA3151909A patent/CA3151909A1/en active Pending
- 2020-09-03 EP EP20860175.7A patent/EP4026564A4/en not_active Withdrawn
- 2020-09-03 EP EP23196223.4A patent/EP4342466A1/en active Pending
- 2020-09-03 AU AU2020341926A patent/AU2020341926B2/en active Active
- 2020-09-03 KR KR1020227010592A patent/KR20220056219A/ko active Pending
- 2020-09-03 JP JP2021544029A patent/JP7692832B2/ja active Active
- 2020-09-03 CN CN202080076112.9A patent/CN114585387B/zh active Active
- 2020-09-03 MX MX2022002683A patent/MX2022002683A/es unknown
-
2025
- 2025-03-25 JP JP2025050332A patent/JP2025094217A/ja not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011002011A1 (ja) * | 2009-07-01 | 2011-01-06 | キッセイ薬品工業株式会社 | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |
| JP2018115216A (ja) * | 2011-08-31 | 2018-07-26 | 日本たばこ産業株式会社 | ピラゾール化合物及びその医薬用途 |
| JP2015516419A (ja) * | 2012-05-10 | 2015-06-11 | イーライ リリー アンド カンパニー | Ｓｇｌｔ１阻害剤としてのピラゾール化合物 |
| JP7206132B2 (ja) * | 2018-03-01 | 2023-01-17 | 日本たばこ産業株式会社 | メチルラクタム環化合物及びその医薬用途 |
| JP7130588B2 (ja) * | 2018-04-04 | 2022-09-05 | 日本たばこ産業株式会社 | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022003323A2 (pt) | 2022-05-24 |
| US20230119894A1 (en) | 2023-04-20 |
| AU2020341926A1 (en) | 2022-03-17 |
| EP4342466A1 (en) | 2024-03-27 |
| AU2020341926B2 (en) | 2026-02-26 |
| EP4026564A1 (en) | 2022-07-13 |
| KR20220056219A (ko) | 2022-05-04 |
| JP2025094217A (ja) | 2025-06-24 |
| JP7692832B2 (ja) | 2025-06-16 |
| MX2022002683A (es) | 2022-04-07 |
| CA3151909A1 (en) | 2021-03-11 |
| WO2021045159A1 (ja) | 2021-03-11 |
| EP4026564A4 (en) | 2023-03-15 |
| CN114585387B (zh) | 2024-10-29 |
| CN114585387A (zh) | 2022-06-03 |
| CN119113123A (zh) | 2024-12-13 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230901 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240813 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250502 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250527 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250604 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7692832 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |